On May 22, 2025, Verastem, Inc. held its annual stockholders meeting where directors were elected, Ernst & Young was confirmed as the independent auditor, and the compensation for executive officers was approved, along with announcing successful clinical trial results showing 83% response in patients treated with their drug combination for pancreatic cancer.